Medivir AB (publ) (MVRBF) Research

Medivir AB (publ), established in 1987 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to the discovery, development, and commercialization of medicines, with a primary emphasis on oncology. The company's operations span both Sweden and international markets. Currently, Medivir markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its pipeline of developmental compounds includes Remetinostat, an investigational therapy for MF cutaneous T-cell lymphoma and basal cell carcinoma. Additionally, the company is advancing MIV-818 for liver cancer, MIV-711 for osteoarthritis, and both Birinapant and IGM-8444, which are being developed to address solid tumors. Medivir also actively participates in collaborative ventures, such as a research partnership with the Drug Discovery and Development Platform at SciLifeLab focused on identifying antivirals for SARS CoV-2. Furthermore, it maintains licensing agreements with Tango Therapeutics for a preclinical research initiative and with Ubiquigent Limited for a preclinical program targeting USP7.

Open Medivir AB (publ) (MVRBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.